[Evaluation of clinical efficacy and safety of cefpodoxime proxetil (CPDX-PR) in acute uncomplicated cystitis].
One hundred and fifty female patients with acute uncomplicated cystitis were given 200 mg of CPDX-PR twice daily for 3-7 days to evaluate both its overall clinical efficacy and its adverse effects. In 82 cases (Group I) in which it was administered for 3 days, the overall clinical efficacy, evaluated by the criteria proposed by the Japanese UTI committee, was excellent in 64 cases, moderate in 17 and poor in one, with the effective rate being 98.8%. In 35 cases (Group II) in which it was administered for 4-7 days, the overall clinical efficacy was excellent in 18 cases, moderate in 15 and poor in 2, with the effective rate being 94.3%. The overall clinical evaluation was not performed in another 33 cases because they were given CPDX-PR for more than 8 days or 300 mg/day. Subjective adverse effects such as hoarseness and lingual inflammation were observed in only one of the 150 cases, but they disappeared spontaneously after the cessation of administration of CPDX-PR. These findings suggest that CPDX-PR is one of the most effective and safe antibiotic in the treatment of acute uncomplicated cystitis.
Furusawa
T
T
Department of Urology, Kyoto 2nd Red Cross Hospital.
Hiratake
Y
Y
Mishina
T
T
Ooe
H
H
Maegawa
M
M
Furudama
H
H
Hida
S
S
Itoh
M
M
Inoue
S
S
Nakagawa
K
K
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000097627:Cefpodoxime Proxetil
D015296:Ceftizoxime; D000097627:Cefpodoxime Proxetil